West Virginia Medicaid GLP-1 Coverage 2026: Categorical Exclusion + Three FDA-Label Carve-Outs (Wegovy CV + Wegovy MASH + Zepbound OSA) via WVU Rational Drug Therapy Program

TL;DR

West Virginia Medicaid (administered by the Bureau for Medical Services (BMS) within the WV Department of Human Services) does NOT cover GLP-1 receptor agonists for chronic weight management. The BMS Office of Pharmacy Services PA criteria documents for Wegovy and Zepbound both state verbatim: “Agents used for the purpose of weight loss are typically a benefit exclusion.”

Three FDA-label-restricted carve-outs are operationalized through the WVU Rational Drug Therapy Program (RDTP) at the West Virginia University School of Pharmacy:

Architectural distinctive features:

• WVU School of Pharmacy PA model. West Virginia is one of three states in the 36-state series using a state university school of pharmacy for PA processing — alongside Oklahoma (OU College of Pharmacy / PMC for SoonerCare) and Arkansas (ULM College of Pharmacy / Prime Therapeutics State Government Solutions for FFS PA Desk).
• Gainwell Technologies PBM. Pharmacy claims processing through Gainwell's Provider Help Desk (1-888-483-0801) and Member Help Desk (1-888-483-0797); point-of-sale adjudication separate from PA review.
• HbA1c ≤ 6.5% gate on Wegovy CV. WV uniquely routes T2D-CVD patients OUT of the Wegovy CV carve-out and INTO the T2D pathway (Hypoglycemics-Incretin Mimetics class on the PDL).
• T2D step-therapy bridge on Zepbound OSA. T2D-OSA patients must first fail a preferred T2D GLP-1 compliantly for three months before Zepbound OSA coverage becomes available. Unique in the 36-state series.
• Wegovy CV + MASH in the same PA document. WV uses a single Wegovy PA Criteria document (effective Jan 1, 2026) covering both indications. Arkansas (Pattern #34) uses three separate standalone PA documents for its three carve-outs.

Medicaid expansion status: WV expanded Medicaid under the Affordable Care Act effective January 1, 2014, covering adults 19–64 at or below 138% of the federal poverty level. Approximately 520,000 West Virginians are enrolled in Medicaid as of 2026, including the expansion population. WV is structurally distinct from non-expansion southern states (AL, FL, GA, KS, MS, SC, TN, TX, WI, WY) in this regard, but the categorical chronic-weight-management exclusion applies uniformly.

1. Federal authority and the WV categorical exclusion

The federal Medicaid drug rebate statute at 42 U.S.C. § 1396r-8(d)(2)(A) grants states an optional authority to exclude “Agents when used for anorexia, weight loss, or weight gain” from coverage. West Virginia has exercised this authority — categorically — and has NOT executed a State Plan Amendment carve-back-in for chronic weight management (unlike Mississippi's SPA 23-0013, the only non-expansion southern state with affirmative chronic-weight-management coverage in the 36-state series).

The verbatim categorical-exclusion language appears in BOTH WV BMS Office of Pharmacy Services PA criteria documents for the two GLP-1 agents with published PA criteria:

1.1 Wegovy PA Criteria (effective January 1, 2026) — verbatim

“Agents used for the purpose of weight loss are typically a benefit exclusion. Coverage of Wegovy will only be considered for the secondary prevention of a cardiovascular event and/or a diagnosis of MASH.”

1.2 Zepbound PA Criteria (effective July 1, 2025) — verbatim

“Agents used for the purpose of weight loss are typically a benefit exclusion and not covered by West Virginia Medicaid. Coverage of Zepbound will only be considered for a diagnosis of OSA in adults with obesity.”

The Zepbound document is more emphatic than the Wegovy document on the categorical-exclusion language — explicitly stating “not covered by West Virginia Medicaid.” Both documents operate at the BMS Office of Pharmacy Services policy level rather than at a state administrative-code rule level (unlike Mississippi Pattern #35, which anchors the exclusion in Miss. Admin. Code Title 23 Part 214 Rule 1.3.B.1). The BMS criteria are subject to ongoing Office of Pharmacy Services modification through the WV Medicaid Pharmacy and Therapeutics (P&T) Committee recommendation process.

2. Wegovy CV carve-out (effective January 1, 2026)

Per the WV BMS Office of Pharmacy Services Wegovy PA Criteria (effective January 1, 2026), the verbatim criteria for cardiovascular risk reduction:

“CRITERIA FOR APPROVAL for reduction of major adverse cardiovascular events:

1. Patient is within the age range as recommended by the Food and Drug Administration (FDA) label; AND

2. The patient has a documented Body Mass Index (BMI) of 27 kg/m² or greater (date and results of the most recent BMI calculation are stated on the request); AND

3. Must be prescribed by or in consultation with an M.D./D.O. or a specialty trained prescriber with a clinical specialty certification/degree in cardiology, vascular surgery or neurology; AND

4. The patient has had at least ONE of the following:

a) Prior myocardial infarction; or

b) Prior stroke; or

c) Symptomatic peripheral arterial disease (PAD) as demonstrated by one of the following:

1. Formal vascular laboratory testing showing intermittent claudication with ankle-brachial systolic pressure index (ABI) of ≤ 0.85 at rest; or

2. Peripheral revascularization procedure; or

3. Amputation due to atherosclerotic disease; AND

5. The patient attests to behavioral modification including a reduced calorie diet and increased physical activity; AND

6. HbA1c level taken within the last 6 months must be provided; AND

7. The patient does not have any of the following:

a) Type 1, type 2 diabetes

b) HbA1c > 6.5%; AND

8. The medication will not be used with other GLP-1 agonist agents.”

Initial approval: 90 days. Continuation of therapy requires the patient to be at an appropriate maintenance dose (1.7 mg or 2.4 mg per week). If the 1.7 mg dose is intolerable, the medication must be discontinued. Continuation approvals are granted for six months at a time.

2.1 The HbA1c ≤ 6.5% diabetic-exclusion gate

Criterion #7 is structurally unique in the 36-state series. WV uniquely routes T2D patients (and prediabetics with HbA1c > 6.5%) OUT of the Wegovy CV carve-out. The operational consequence: a T2D patient with established CVD who would meet FDA-label criteria for Wegovy CV cannot use this carve-out under WV Medicaid — they must instead access a T2D-indicated GLP-1 (such as Ozempic, which carries an FDA cardiovascular indication, or Trulicity, which also carries one) under the Hypoglycemics-Incretin Mimetics PDL class T2D PA pathway.

Rationale (inferred from WV BMS structure): T2D-CVD patients have well-established T2D-indicated GLP-1 therapeutic alternatives that overlap meaningfully with the Wegovy CV indication. Routing T2D-CVD patients through the T2D pathway simplifies prior-authorization adjudication (one criteria document covers both indications) and avoids dual-criteria-document duplication. The cost: T2D patients seeking semaglutide specifically for CV risk reduction must go through Ozempic (a different formulation of semaglutide) rather than Wegovy.

2.2 Specialty consultation requirement

Wegovy CV approval requires the prescription to be “prescribed by or in consultation with an M.D./D.O. or a specialty trained prescriber with a clinical specialty certification/degree in cardiology, vascular surgery or neurology.” A primary-care physician can prescribe Wegovy CV in West Virginia only after documented consultation with one of these specialists. This concentrates CV indication review at the specialist level and ensures the secondary-prevention rationale is anchored to specialist assessment.

2.3 PAD documentation specificity

For peripheral arterial disease, WV requires specific documented evidence: ABI ≤ 0.85 at rest on formal vascular laboratory testing OR documented peripheral revascularization procedure OR amputation due to atherosclerotic disease. This is more specific than many other state Medicaid Wegovy CV carve-outs, which accept generic PAD diagnosis codes without ABI quantification.

3. Wegovy MASH carve-out (same PA document, effective January 1, 2026)

The MASH (metabolic dysfunction-associated steatohepatitis, formerly NASH) carve-out shares the same Wegovy PA Criteria document as the CV carve-out. Verbatim:

“CRITERIA FOR APPROVAL for noncirrhotic metabolic dysfunction (MASH):

1. Patient has a diagnosis of noncirrhotic metabolic dysfunction associated steatohepatitis (MASH) with moderate to advanced liver fibrosis; AND

2. Diagnosis of MASH is confirmed by ONE of the following:

a) Liver biopsy within the past 1 year and the results show nonalcoholic fatty liver disease activity score of ≥ 4 with a score of > 1 in ALL the following: Steatosis, Ballooning, and Lobular inflammation; OR

b) Liver stiffness measurement by vibration-controlled transient elastography (e.g. FibroScan) or magnetic resonance elastography (MRE); AND

3. The patient has stage 2 or stage 3 fibrosis; AND

4. Patient is within the age range as recommended by the Food and Drug Administration (FDA) label; AND

5. Must be prescribed by, or in consultation, with an M.D./D.O. or a specialty trained prescriber with a clinical specialty certification/degree in gastroenterology or hepatology; AND

6. The medication will be used in combination with appropriate diet and exercise therapy (Please describe and submit documentation of diet, exercise and weight loss counseling/treatment provided within the past 12 months); AND

7. The patient is compliant on stable dosages of medications for diabetes, dyslipidemia, and hypertension (where applicable); AND

8. For patients with both type 2 diabetes and MASH, therapy for type 2 diabetes should be managed with a GLP-1 receptor agonist approved for that indication at the appropriate dose (please refer to the diabetes GLP-1 receptor agonist class on the West Virginia Preferred Drug List).

9. The medication will not be used with other GLP-1 agonist agents.”

Initial approval: 90 days. Continuation criteria require: (1) patient continues to meet all initial criteria; (2) documented compliance; (3) patient has not progressed to stage F4 (cirrhosis); (4) documented positive clinical response — either resolution of steatohepatitis without worsening fibrosis, OR at least one stage of fibrosis improvement without worsening steatohepatitis. Continuation approvals are granted for one year after all criteria are met.

3.1 Biopsy or imaging requirement

WV accepts either liver biopsy with NAFLD activity score ≥ 4 (steatosis + ballooning + lobular inflammation each > 1) OR vibration-controlled transient elastography (FibroScan) or magnetic resonance elastography (MRE). This is consistent with the current MASH/MASLD clinical practice guidance (the AASLD 2023 guidelines accept non-invasive imaging as a fibrosis assessment modality). Patients who cannot tolerate biopsy can still qualify through FibroScan/MRE evidence.

3.2 The dual-pathway-for-T2D-MASH rule

Criterion #8 mirrors the CV criteria's exclusion of T2D patients but operates differently: a T2D + MASH patient is NOT categorically excluded from the Wegovy MASH carve-out, but their T2D therapy must be managed with a T2D-indicated GLP-1 at the appropriate dose. The patient receives BOTH a T2D-indicated GLP-1 (under the Hypoglycemics-Incretin Mimetics PDL class) AND Wegovy for MASH — subject to criterion #9, which categorically excludes concurrent GLP-1 agonist use.

This creates an operational tension: the rule appears to require concurrent dual GLP-1 therapy for T2D + MASH patients, while also categorically excluding it. The resolution: in practice, T2D + MASH patients should be evaluated by their gastroenterologist or hepatologist together with their endocrinologist or primary-care provider to select a single GLP-1 strategy. Either (a) the T2D-indicated GLP-1 (Ozempic) is used as monotherapy for both T2D and MASH (Ozempic does not carry an FDA MASH indication but has published evidence supporting MASH benefit), or (b) Wegovy is used with T2D managed through non-GLP-1 therapy (metformin, SGLT2 inhibitors, insulin). The WV PA Desk will typically deny dual concurrent GLP-1 prescriptions on criterion #9.

4. Zepbound OSA carve-out (effective July 1, 2025)

Per the WV BMS Office of Pharmacy Services Zepbound PA Criteria (effective July 1, 2025), the verbatim approval criteria:

“CRITERIA FOR APPROVAL:

1. The patient is within the age range as recommended by the Food and Drug Administration (FDA) label; AND

2. The patient has a diagnosis of moderate to severe OSA with a sleep study within the past twelve months confirming an apnea-hypopnea index (AHI) greater than or equal to fifteen events per hour; AND

3. The patient has a diagnosis of obesity with a documented Body Mass Index (BMI) of 30 kg/m² or greater within the past three months (date and results of the most recent weight and BMI calculation are stated on the request); AND

4. The patient has been prescribed or counseled on the use of continuous airway pressure (CPAP) as a potential therapy; AND

5. The patient has received counseling on chronic weight management (increased physical activity and a reduced calorie diet) and will continue to receive ongoing counseling during combination treatment with Zepbound; AND

6. Patients who have a concurrent diagnosis of Type II Diabetes Mellitus (DM) have been trialed on a preferred GLP-1 (indicated for Type II DM) compliantly for three months and experienced treatment failure; AND

7. The patient is not receiving ZEPBOUND in combination with other tirzepatide-containing products or with any other agents in the GIP/GLP-1 class.”

Initial approval: 150 days. Reauthorization criteria:

“CRITERIA FOR REAUTHORIZATION:

1. Demonstrate continued documented compliance; AND

2. The patient has been able to tolerate AT LEAST a 10 mg maintenance dose; AND

3. The patient will continue to follow a reduced calorie diet and increased physical activity plan; AND

4. Clinical improvement of OSA while on ZEPBOUND® (such as, patient-reported improvement in daytime sleepiness, partner-reported reduction of snoring episodes or pauses in breathing, reduction of AHI events, etc.); AND

5. The patient has shown a documented weight loss of > 5% or continued to maintain initial 5% weight loss.”

Further approvals are granted for six months after all continuation criteria are met. All fills are limited to a 30-day supply.

4.1 The T2D step-therapy bridge (criterion #6)

Criterion #6 is structurally unique in the 36-state series. T2D patients seeking Zepbound for OSA must first demonstrate compliant trial of a preferred T2D GLP-1 for three months with documented treatment failure. Acceptable preferred T2D GLP-1 trials would include Ozempic (semaglutide), Mounjaro (tirzepatide — the same active ingredient as Zepbound but at a T2D-indicated dose tier), Trulicity (dulaglutide), Victoza (liraglutide), Rybelsus (oral semaglutide), or Byetta (exenatide), depending on which agents are Preferred on the current WV PDL Hypoglycemics-Incretin Mimetics class.

Operational implication: T2D + OSA patients face a longer pathway to Zepbound OSA than non-T2D OSA patients. The three-month trial period plus documentation of treatment failure adds approximately 90–120 days to the Zepbound OSA approval timeline. T2D patients should plan for this with their prescriber and document baseline OSA severity (AHI), CPAP tolerance, and T2D-GLP-1 trial outcomes throughout the trial period.

4.2 CPAP counseling (not failure) requirement

Notably, criterion #4 requires only that the patient be “prescribed or counseled on the use of continuous airway pressure (CPAP) as a potential therapy.” This is more permissive than other state Medicaid Zepbound OSA carve-outs (e.g., Arkansas Pattern #34 requires documented CPAP failure for 6 months with adherence data; Oklahoma Pattern #24 has similar adherence requirements). WV does not require CPAP failure or adherence documentation — only that CPAP was prescribed or counseled as a potential therapy.

Operational implication: A patient who is offered CPAP, accepts the prescription, and then chooses Zepbound as a primary OSA therapy (without CPAP failure) can qualify in WV. This is patient-centered relative to states requiring documented CPAP failure.

5. WVU Rational Drug Therapy Program (RDTP)

The WVU Rational Drug Therapy Program is the West Virginia University School of Pharmacy's prior-authorization review operation that adjudicates PA requests for WV Medicaid. RDTP processes PA submissions against the BMS Office of Pharmacy Services criteria documents and issues approvals or denials.

Operational contacts:

• RDTP Phone: 1-800-847-3859
• RDTP Fax: 1-800-531-7787
• Gainwell Provider Help Desk: 1-888-483-0801
• Gainwell Member Help Desk: 1-888-483-0797
• BMS Office of Pharmacy Services: 304-558-1700 (Charleston)
• BMS Fax: 304-558-1451 or 304-558-1542 (varies by criteria document)

5.1 The university-pharmacy-school PA model

West Virginia is one of three states in the 36-state series using a state university school of pharmacy as the PA processing infrastructure:

• West Virginia (Pattern #36): WVU Rational Drug Therapy Program at WVU School of Pharmacy.
• Oklahoma (Pattern #24): Pharmacy Management Consultants (PMC) at the OU College of Pharmacy for SoonerCare PA review.
• Arkansas (Pattern #34): University of Louisiana at Monroe (ULM) College of Pharmacy operates the FFS PA Desk under contract with Prime Therapeutics State Government Solutions.

Why university-pharmacy-school PA models exist:

• Centralized clinical expertise. University pharmacy faculty/staff with prescription-drug clinical training concentrate PA review under a single statewide entity rather than distributing it across MCO-specific PBMs.
• Educational pipeline. Pharmacy students rotate through PA Desk operations as part of their PharmD curriculum, providing structured training in formulary policy, evidence-based prescribing review, and Medicaid drug benefit administration.
• State-public-employee-cost containment. University pharmacy faculty are state public employees; their hourly cost is typically lower than commercial PBM contract review (though MCO PBMs achieve scale economies that university pharmacy schools do not).
• Limited commercial-PBM bias. University-administered PA review is structurally less likely to favor specific manufacturer rebate-bearing brands than commercial PBM-administered review, where rebate dynamics can influence formulary preference.

5.2 How to submit a PA request to WVU RDTP

Prior authorization requests for Wegovy or Zepbound under WV Medicaid follow this workflow:

1. Prescriber completes the Prior Authorization Request Form linked from the BMS Office of Pharmacy Services criteria document (each carve-out has its own form).
2. Prescriber attaches supporting documentation: for Wegovy CV — BMI documentation, established CVD evidence (PAD ABI report, MI/stroke records, revascularization or amputation documentation), HbA1c value within past 6 months, specialty consult note. For Wegovy MASH — biopsy report or FibroScan/MRE result, fibrosis staging, GI/hepatology consult, diet/exercise documentation past 12 months. For Zepbound OSA — sleep study with AHI value within past 12 months, BMI documentation within past 3 months, CPAP prescription/counseling note, T2D step-therapy documentation if applicable.
3. Submit by fax to RDTP at 1-800-531-7787 or via the WVU RDTP web portal.
4. RDTP reviews against criteria and issues approval (90-day for Wegovy CV/MASH; 150-day for Zepbound OSA) or denial with rationale.
5. If approved, the pharmacy can dispense up to a 30-day supply per fill (Zepbound is explicitly limited to 30-day supply per fill).
6. If denied, the patient or prescriber can request reconsideration with additional documentation or file a formal appeal with the WV DHS Board of Review (see appeals section below).

6. What WV Medicaid covers vs. does not cover

Key observations:

• Saxenda (liraglutide) has no published WV PA criteria document. Saxenda is structurally similar to Wegovy (both are GLP-1 receptor agonists from Novo Nordisk with chronic- weight-management FDA labels) but does not have a CV indication or MASH indication. Under WV's categorical exclusion, Saxenda is therefore presumptively non-covered — the absence of a published PA criteria document confirms this.
• Foundayo (orforglipron), the newly FDA-approved oral GLP-1 receptor agonist (April 2026 approval), has no published WV PA criteria document as of the most recent BMS PA criteria page review (May 14, 2026 PDL revision). Foundayo is therefore presumptively non-covered under WV's categorical exclusion.
• Off-label T2D-indicated GLP-1 prescribing for chronic weight management is not reimbursed. A patient seeking Ozempic for weight loss (off-label) cannot obtain coverage under the Hypoglycemics-Incretin Mimetics class without a documented T2D diagnosis.

7. The WV Medicaid Preferred Drug List

The WV Medicaid PDL is maintained by the BMS Office of Pharmacy Services with quarterly review by the WV Medicaid P&T Committee. The current PDL version is effective April 1, 2026, revised May 14, 2026 — one day before this article's verification date (May 15, 2026). The BMS Office of Pharmacy Services PDL page states: “The PDL only addresses certain drug classes. Some classes of drugs will not be reviewed for preferential agents because of no or limited cost savings.”

Anti-obesity drug class: WV does not maintain an “Anti-obesity Agents” class on the PDL (unlike Mississippi Pattern #35's “Antiobesity Select Agents” class with Wegovy + Saxenda Preferred). The absence of a PDL class for anti-obesity drugs is consistent with WV's categorical non-coverage posture — there is nothing to list as Preferred or Non-Preferred because nothing is covered for chronic weight management.

Hypoglycemics-Incretin Mimetics class: covers the T2D-indicated GLP-1 agents (Ozempic, Mounjaro, Trulicity, Victoza, Rybelsus, Byetta, Bydureon) with PA for an FDA-approved T2D diagnosis. Preferred and Non-Preferred status is set by the WV P&T Committee and is subject to rebate-agreement and clinical review.

The Wegovy PA Criteria document references the WV PDL for T2D management: criterion #8 of the Wegovy MASH criteria states “please refer to the diabetes GLP-1 receptor agonist class on the West Virginia Preferred Drug List.” This cross-reference establishes that T2D + MASH patients must select a Preferred T2D GLP-1 from the current PDL when their MASH therapy is Wegovy.

8. Appeals pathway

WV Medicaid appeals run through the WV Department of Human Services Board of Review under WV Code § 9-2-9 and federal regulations at 42 C.F.R. § 431 Subpart E (Fair Hearings for Applicants and Recipients).

Practical denial-recovery path for a WV Medicaid GLP-1 carve-out denial:

1. Contact WVU RDTP at 1-800-847-3859 to verify the denial rationale. Many denials are documentation deficiencies recoverable through re-submission, not categorical denials.
2. Re-submit the PA with additional clinical evidence:
   • For Wegovy CV: ABI report with quantified value; cardiology / vascular surgery / neurology consult note; HbA1c within past 6 months; documented MI, stroke, revascularization, or amputation.
   • For Wegovy MASH: liver biopsy report with NAFLD activity score quantified, OR FibroScan/MRE report with fibrosis stage; GI / hepatology consult; diet/exercise documentation within past 12 months.
   • For Zepbound OSA: sleep study with AHI value documented; BMI within past 3 months; CPAP prescription or counseling note; T2D step-therapy trial documentation if applicable.
3. If RDTP denial stands, file a written request for fair hearing with the WV DHS Board of Review within 90 days of the adverse-action notice.
4. Hearing before an administrative law judgewith the right to representation and to introduce evidence.
5. Final agency decision issued by the WV DHS Board of Review.
6. Judicial review in WV circuit court under the WV Administrative Procedures Act.

Appeal posture for categorical chronic-weight-management denials: these cannot succeed. The exclusion is anchored to 42 U.S.C. § 1396r-8(d)(2)(A) and the explicit “benefit exclusion” language in both BMS PA criteria documents. An appeal contesting the categorical exclusion will be sustained against the patient.

Appeal posture for documentation-deficiency denials: these are the strongest appeals. If the patient demonstrably meets all numbered criteria for Wegovy CV, Wegovy MASH, or Zepbound OSA but the PA was denied for a documentation gap (e.g., HbA1c not reported, sleep study older than 12 months, missing specialist consult note), the appeal can succeed by supplying the missing documentation.

9. West Virginia vs. the 35-state taxonomy

9.1 Vs. categorical-exclusion-plus-carve-out peers

• Oklahoma (Pattern #24) — four carve-outs (Wegovy CV + Wegovy MASH + Zepbound OSA + Imcivree monogenic-obesity). WV has three (no Imcivree). Both use a state university school of pharmacy for PA processing (OU College of Pharmacy / PMC for OK; WVU School of Pharmacy / RDTP for WV).
• Arkansas (Pattern #34) — three carve-outs (Wegovy CV July 2024 + Zepbound OSA April 2025 + Wegovy MASH October 2025) via three separate standalone DUR-Board-approved PA documents. WV combines Wegovy CV + MASH in a single PA document. Both states use a university-pharmacy-school PA model (ULM College of Pharmacy / Prime Therapeutics for AR; WVU School of Pharmacy / RDTP for WV). AR has the additional 2025-legislative-ratification layer (ACT 628 § 20-77-154(c) effective January 1, 2026 explicitly excluding weight-loss drug coverage); WV does not have a parallel legislative ratification.
• Alabama (Pattern #23) — non-expansion southern state with PDL-enumerated Zepbound OSA carve-out (PDL footnote ^) and off-PDL Wegovy MACE PA Form 369. Both states have Zepbound OSA carve-outs but the operational architecture differs (AL uses PDL footnote; WV uses standalone PA criteria document). AL has no Wegovy MASH carve-out; WV does. AL is non-expansion; WV is expansion (eff. January 1, 2014).
• Kentucky (Pattern #21) — nullified-amendment exclusion state with OSA Zepbound + MACE Wegovy via stand-alone PA PDFs on the MedImpact portal. WV and KY share the standalone PA PDF architecture but with different PBMs (WV: Gainwell; KY: MedImpact) and different PA processors (WV: WVU RDTP; KY: MedImpact).

9.2 Vs. Mississippi (Pattern #35) — non-expansion-southern positive coverage

WV and MS represent opposite policy postures within the broader regional cluster. Mississippi (a non-expansion southern state) executed SPA 23-0013 (effective July 1, 2023) to carve back in chronic-weight-management coverage of Wegovy + Saxenda for ages 12 and older. West Virginia (an expansion state — ACA expansion effective January 1, 2014) has NOT executed an SPA carve-back-in — it remains in categorical-exclusion-with-FDA- label-carve-outs posture. The structural take-away: Medicaid expansion status does NOT predict chronic-weight-management coverage posture. WV (expanded) does not cover for weight management; MS (non-expansion) does.

9.3 Distinctive features

West Virginia (Pattern #36) is the only state in the 36-state series with:

• The HbA1c ≤ 6.5% gate on the Wegovy CV carve-out — categorically excluding T1D and T2D patients from the Wegovy CV pathway and routing them to the T2D PDL class instead. No other state in the series has this specific HbA1c-based exclusion gate.
• The T2D step-therapy bridge on the Zepbound OSA carve-out — T2D patients must first fail a preferred T2D GLP-1 compliantly for three months before Zepbound OSA coverage becomes available. No other state in the series has this specific T2D step-therapy precondition for OSA coverage.
• Wegovy CV + MASH bundled in a single PA criteria document — effective January 1, 2026 for both indications. Most other states (AR, OK) use separate documents per indication.
• The WVU Rational Drug Therapy Program (RDTP) PA model — alongside OK's OU College of Pharmacy / PMC and AR's ULM College of Pharmacy / Prime Therapeutics, WV is one of only three university-pharmacy-school PA states in the 36-state series.

Frequently asked questions